We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Biopharma Credit Plc | LSE:BPCR | London | Ordinary Share | GB00BDGKMY29 | ORD USD0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.878 | 0.876 | 0.88 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 135.74M | 108.45M | 0.0833 | 10.56 | 1.15B |
TIDMBPCR
RNS Number : 3691H
BioPharma Credit PLC
14 November 2018
TR-1: Standard form for notification of major holdings
Hot Features
Premium
NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the BioPharma Credit PLC
underlying issuer of existing shares
to which voting rights are attached:
----------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify): x
Adage % of Voting Rights decreased due to Equity Offering listed
on 05/11/2018 increasing Total Voting Rights
(prior to the offering, there was also the conversion of GB00BDRNW621
to GB00BDGKMY29)
----
3. Details of person subject to the notification obligation
Name Adage Capital Partners GP LLC
City and country of registered office Boston, MA, USA
(if applicable)
4. Full name of shareholder(s) (if different from 3.)
Name Morgan Stanley & Co LLC
GB00BDGKMY29 common stock 25,284,247
JP Morgan Securities LLC
GB00BDGKMY29 common stock 73,829,440
----------------------------------------------
City and country of registered office New York, NY USA
(if applicable)
----------------------------------------------
5. Date on which the threshold was 05/11/2018
crossed or reached(vi) :
----------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 12/11/2018
----------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ ---------------------- --------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 7.21% N/A 7.21% 1,373,932,067
------------------ ---------------------- --------------- --------------------
Position of
previous notification
(if
applicable) 9.25% N/A 9.25%
------------------ ---------------------- --------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
----------------------------
GB00BDGKMY29 99,113,687 7.21%
---------------------- ---------------------------- ------------------------- ---------------------
SUBTOTAL 8. A 99,113,687 7.21%
---------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion Period rights that may rights
instrument be acquired if
the instrument
is
exercised/converted.
------------ ------------------------------- -------------------------------- ---------------------
N/A
------------ ------------------------------- -------------------------------- ---------------------
SUBTOTAL 8. B 1
------------------------------- -------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date Conversion cash voting rights rights
instrument Period settlement
----------------- -------------------- --------------------- --------------------
N/A
------------ -------------------- --------------------- --------------------
SUBTOTAL 8.B.2
--------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional
rows as necessary)
Name(xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
---------------------- --------------------- ------------------------
JP Morgan Securities
LLC 5.37% 5.37%
---------------------- --------------------- ------------------------
Morgan Stanley &
Co LLC 1.84% 1.84%
---------------------- --------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
-----------------------------------------------
The number and % of voting rights
held
-----------------------------------------------
The date until which the voting rights
will be held
-----------------------------------------------
11. Additional information
Place of completion Boston, MA USA
Date of completion 12/11/2018
---------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLUSASRWVAAAAA
(END) Dow Jones Newswires
November 14, 2018 10:00 ET (15:00 GMT)
1 Year Biopharma Credit Chart |
1 Month Biopharma Credit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
